OBJECTIVE： To determine the effectiveness of modified Sanhuang Xiexin Tang （SHXXT） plus additional herbs （MSAH） combined with ＂standard tri- ple therapy＂ for eradication of Helicobacter pylori （H. pylori） and...OBJECTIVE： To determine the effectiveness of modified Sanhuang Xiexin Tang （SHXXT） plus additional herbs （MSAH） combined with ＂standard tri- ple therapy＂ for eradication of Helicobacter pylori （H. pylori） and amelioration of related symptoms in comparison with standard triple and standard quadruple therapies. METHODS： From October 2015 to May 2016, we recruited patients with dyspepsia symptoms con- firmed to have H. pylori infection by the ^13C urea breath test in our outpatient clinic. Patients were randomly divided into three treatment groups： Nexium standard triple therapy （group A, EAC）, Nexium standard quadruple therapy （group B, EBAC）, or Nexium standard triple therapy combined with MSAH （group C; EAC＋MSAH）. Comparisons of H. pylori eradication and symptom amelioration rates were made among the three groups at 2 or 6 weeks after group assignment. RESULTS： There was no difference in H. pylori eradication rates between groups B （EBAC） and C （EAC＋ MSAH） （P = 0.486）, and eradication rates in groups B and C were significantly higher than that in group A （EAC） （P Av, e = 0.001; P AvsC= 0.003）. There was no difference in the total symptom score among the groups before treatment. In all groups, the total symptom scores after treatment （2 or 6 weeks after group assignment） were significantly lower than those before treatment （P 〈 0.001 for all）. However, group C （EAC ＋ MSAH） demonstrated superior total symptom scores and symptom amelioration rates than groups A （EAC） and B （EBAC）. Group B also demonstrated better scores and rates than group A. There was no difference in symptom amelioration rates at 2 and 6 weeks within each group. CONCLUSION： There is no difference between MSAH combined with standard triple therapy and standard quadruple therapy containing bismuth with regard to H. pylori eradication rate. However, MSAH combined with standard triple therapy has a higher symptom amelioration rate and therefore appears to be an ideal treatment scheme for H. pyIori eradication.展开更多
AIM: To investigate the effects of San-Huang-Xie-XinTang(SHXXT), a herbal product used in traditional Chinese medicine, on gastrointestinal(GI) motility in mice.METHODS: The in vivo effects of SHXXT on GI motility wer...AIM: To investigate the effects of San-Huang-Xie-XinTang(SHXXT), a herbal product used in traditional Chinese medicine, on gastrointestinal(GI) motility in mice.METHODS: The in vivo effects of SHXXT on GI motility were investigated by measuring the intestinal transit rates(ITRs) using Evans blue in normal mice and in mice with experimentally induced GI motility dysfunction(GMD).RESULTS: In normal ICR mice, ITRs were significantly and dose-dependently increased by SHXXT(0.1-1 g/kg). GMD was induced by injecting acetic acid or streptozotocin intraperitoneally. The ITRs of GMD mice were significantly reduced compared to normal mice, and these reductions were significantly and dose-dependently inhibited by SHXXT(0.1-1 g/kg).CONCLUSION: These results suggest that SHXXT is a novel candidate for the development of a prokinetic agent that may prevent or alleviate GMD.展开更多
目的系统评价半夏泻心汤为主治疗反流性食管炎的临床疗效。方法计算机检索维普数据库(VIP)、中国知识资源总库(CNKI)、万方数据库,纳入以半夏泻心汤为主治疗反流性食管炎的随机对照临床试验或半随机对照临床试验,检索时限均从建库至2015...目的系统评价半夏泻心汤为主治疗反流性食管炎的临床疗效。方法计算机检索维普数据库(VIP)、中国知识资源总库(CNKI)、万方数据库,纳入以半夏泻心汤为主治疗反流性食管炎的随机对照临床试验或半随机对照临床试验,检索时限均从建库至2015年6月,对纳入研究的文献方法学质量进行评价,用Rev Man 5.3软件进行统计分析。结果共纳入11篇文献,合计1305例患者。Meta分析结果显示,与对照组相比半夏泻心汤为主治疗反流性食管炎在临床总有效率[OR=4.16,95%CI(2.91,5.95)]及复发率[OR=0.27,95%CI(0.15,0.48)]方面具有一定的优势,差异均有统计学意义。结论现有研究文献表明半夏泻心汤对反流性食管炎在总有效率及复发率方面优于单纯西医组。但由于纳入研究文献数量和质量有限,上述结论尚需开展大样本、高质量、多中心的研究文献进一步验证,为临床和科研工作者提供更加科学、准确的参考依据。展开更多
文摘OBJECTIVE： To determine the effectiveness of modified Sanhuang Xiexin Tang （SHXXT） plus additional herbs （MSAH） combined with ＂standard tri- ple therapy＂ for eradication of Helicobacter pylori （H. pylori） and amelioration of related symptoms in comparison with standard triple and standard quadruple therapies. METHODS： From October 2015 to May 2016, we recruited patients with dyspepsia symptoms con- firmed to have H. pylori infection by the ^13C urea breath test in our outpatient clinic. Patients were randomly divided into three treatment groups： Nexium standard triple therapy （group A, EAC）, Nexium standard quadruple therapy （group B, EBAC）, or Nexium standard triple therapy combined with MSAH （group C; EAC＋MSAH）. Comparisons of H. pylori eradication and symptom amelioration rates were made among the three groups at 2 or 6 weeks after group assignment. RESULTS： There was no difference in H. pylori eradication rates between groups B （EBAC） and C （EAC＋ MSAH） （P = 0.486）, and eradication rates in groups B and C were significantly higher than that in group A （EAC） （P Av, e = 0.001; P AvsC= 0.003）. There was no difference in the total symptom score among the groups before treatment. In all groups, the total symptom scores after treatment （2 or 6 weeks after group assignment） were significantly lower than those before treatment （P 〈 0.001 for all）. However, group C （EAC ＋ MSAH） demonstrated superior total symptom scores and symptom amelioration rates than groups A （EAC） and B （EBAC）. Group B also demonstrated better scores and rates than group A. There was no difference in symptom amelioration rates at 2 and 6 weeks within each group. CONCLUSION： There is no difference between MSAH combined with standard triple therapy and standard quadruple therapy containing bismuth with regard to H. pylori eradication rate. However, MSAH combined with standard triple therapy has a higher symptom amelioration rate and therefore appears to be an ideal treatment scheme for H. pyIori eradication.
基金Supported by National Research Foundation of Korea Grant funded by the Korean government,No.2014R1A5A2009936
文摘AIM: To investigate the effects of San-Huang-Xie-XinTang(SHXXT), a herbal product used in traditional Chinese medicine, on gastrointestinal(GI) motility in mice.METHODS: The in vivo effects of SHXXT on GI motility were investigated by measuring the intestinal transit rates(ITRs) using Evans blue in normal mice and in mice with experimentally induced GI motility dysfunction(GMD).RESULTS: In normal ICR mice, ITRs were significantly and dose-dependently increased by SHXXT(0.1-1 g/kg). GMD was induced by injecting acetic acid or streptozotocin intraperitoneally. The ITRs of GMD mice were significantly reduced compared to normal mice, and these reductions were significantly and dose-dependently inhibited by SHXXT(0.1-1 g/kg).CONCLUSION: These results suggest that SHXXT is a novel candidate for the development of a prokinetic agent that may prevent or alleviate GMD.
文摘目的系统评价半夏泻心汤为主治疗反流性食管炎的临床疗效。方法计算机检索维普数据库(VIP)、中国知识资源总库(CNKI)、万方数据库,纳入以半夏泻心汤为主治疗反流性食管炎的随机对照临床试验或半随机对照临床试验,检索时限均从建库至2015年6月,对纳入研究的文献方法学质量进行评价,用Rev Man 5.3软件进行统计分析。结果共纳入11篇文献,合计1305例患者。Meta分析结果显示,与对照组相比半夏泻心汤为主治疗反流性食管炎在临床总有效率[OR=4.16,95%CI(2.91,5.95)]及复发率[OR=0.27,95%CI(0.15,0.48)]方面具有一定的优势,差异均有统计学意义。结论现有研究文献表明半夏泻心汤对反流性食管炎在总有效率及复发率方面优于单纯西医组。但由于纳入研究文献数量和质量有限,上述结论尚需开展大样本、高质量、多中心的研究文献进一步验证,为临床和科研工作者提供更加科学、准确的参考依据。
